- Home
- HNVR vs VERU Comparison
HNVR vs VERU Comparison
Compare HNVR & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- VERU
- Stock Information
- Founded
- HNVR 2008
- VERU 1971
- Country
- HNVR United States
- VERU United States
- Employees
- HNVR N/A
- VERU N/A
- Industry
- HNVR Commercial Banks
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- HNVR Finance
- VERU Health Care
- Exchange
- HNVR Nasdaq
- VERU Nasdaq
- Market Cap
- HNVR 129.7M
- VERU 107.2M
- IPO Year
- HNVR 2022
- VERU 1990
- Fundamental
- Price
- HNVR $23.79
- VERU $0.63
- Analyst Decision
- HNVR Buy
- VERU Strong Buy
- Analyst Count
- HNVR 1
- VERU 4
- Target Price
- HNVR $22.00
- VERU $4.00
- AVG Volume (30 Days)
- HNVR 15.4K
- VERU 855.8K
- Earning Date
- HNVR 10-23-2024
- VERU 12-06-2024
- Dividend Yield
- HNVR 1.63%
- VERU N/A
- EPS Growth
- HNVR N/A
- VERU N/A
- EPS
- HNVR 1.84
- VERU N/A
- Revenue
- HNVR $64,015,000.00
- VERU $14,091,909.00
- Revenue This Year
- HNVR N/A
- VERU N/A
- Revenue Next Year
- HNVR $18.07
- VERU N/A
- P/E Ratio
- HNVR $13.02
- VERU N/A
- Revenue Growth
- HNVR 6.86
- VERU N/A
- 52 Week Low
- HNVR $13.62
- VERU $0.36
- 52 Week High
- HNVR $25.80
- VERU $1.92
- Technical
- Relative Strength Index (RSI)
- HNVR 81.00
- VERU 34.01
- Support Level
- HNVR $20.03
- VERU $0.57
- Resistance Level
- HNVR $22.04
- VERU $0.64
- Average True Range (ATR)
- HNVR 1.16
- VERU 0.05
- MACD
- HNVR 0.27
- VERU -0.01
- Stochastic Oscillator
- HNVR 70.91
- VERU 21.04
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.